Progyny, Inc. (PGNY) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Progyny, Inc. is a benefits management company specializing in fertility, family building, and women's health solutions. The company operates in a single segment, serving over 550 enterprise clients with approximately 6.7 million covered lives. Its core offerings include the "Smart Cycle" fertility benefits solution and the "Progyny Rx" pharmacy benefits solution.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $313.3 million | $286.6 million | $970.3 million | $868.8 million |
| Gross Profit | $72.8 million | $59.2 million | $227.6 million | $190.0 million |
| Gross Margin | 23.2% | 20.7% | 23.5% | 21.9% |
| Net Income | $13.9 million | $10.4 million | $46.0 million | $43.8 million |
| Diluted EPS | $0.15 | $0.11 | $0.51 | $0.46 |
| Operating Cash Flow (YTD) | $156.0 million (2025) vs $126.9 million (2024) | |||
| Cash & Marketable Securities | $345.2 million (as of Sept 30, 2025) | |||
| Debt | $0 drawn on $200M Revolver (Established July 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 9% year-over-year in Q3 and 12% year-over-year for the nine-month period. This was driven by a 13% increase in fertility benefits revenue and a 3% increase in pharmacy benefits revenue, attributed to growth in the number of clients and covered lives.
- Margin Expansion: Gross margin improved by 250 basis points in Q3 (23.2% vs 20.7%) and 160 basis points YTD, primarily due to efficiencies in care management services.
- Expense Management: Operating expenses increased 10% in Q3 and 14% YTD. General and Administrative (G&A) expenses rose due to incremental headcount and a $1.2 million increase in bad debt expense (Q3) driven by revenue growth. Sales and Marketing expenses increased 9% in Q3.
- Interest Income: Interest and other income decreased 56% in Q3 and 46% YTD compared to the prior year, reflecting lower investment income and higher interest expense.
- Acquisitions: The company completed the acquisition of Benefit Bump LLC in January 2025 for $10.5 million to expand parental leave benefits navigation.
Guidance, Outlook, and Risks
- Guidance: On November 6, 2025, management issued guidance for Q4 and full-year 2025. The filing notes that guidance is forward-looking and subject to revision based on market conditions and utilization trends.
- Liquidity: The company maintains a strong liquidity position with $134.0 million in cash and $211.2 million in marketable securities. A new $200 million revolving credit facility was established in July 2025 with no amounts currently drawn.
- Share Repurchases: In November 2025, the Board authorized a new $200 million share repurchase program. Previous 2024 programs totaling $300 million were completed by year-end 2024.
- Key Risks:
- Client Concentration: While no single client exceeded 10% of revenue in the first nine months of 2025, the company previously had a client representing 12% in 2024 who did not renew. The technology sector remains a significant portion of the client base.
- Regulatory Environment: The company faces evolving regulations regarding reproductive rights, PBM operations, and data privacy (HIPAA, CCPA). Changes in state laws regarding abortion and fertility treatments could impact service availability.
- Utilization Volatility: Revenue is heavily dependent on member utilization rates, which can fluctuate based on economic conditions and member demographics.
Investor Verification Checklist
- Client Retention: Verify the impact of the non-renewal of the large client (12% of 2024 revenue) on full-year 2025 revenue guidance and future renewal rates.
- Utilization Trends: Monitor the "Utilization - All Members" metric (0.54% in Q3 2025) to ensure it remains stable or grows, as this is a primary revenue driver.
- Bad Debt Exposure: Review the allowance for doubtful accounts ($54.6 million) and the trend in bad debt expense, which increased significantly in 2025.
- Regulatory Compliance: Assess the potential financial impact of new state-level reproductive rights legislation and PBM regulations on the Progyny Rx segment.
- Cash Flow Sustainability: Confirm that operating cash flow continues to outpace capital expenditures and that the new credit facility remains undrawn as a liquidity buffer.